Melatonina Sr
Referências:
1. Zhao D, Yu Y, Shen Y, et al. Melatonin synthesis and function: Evolutionary history in animals and plants. Front Endocrinol (Lausanne). 2019;10(APR):1-16. doi:10.3389/fendo.2019.00249
2. Claustrat B, Leston J. Melatonin: Physiological effects in humans. Neurochirurgie. 2015;61(2-3):77-84. doi:10.1016/j.neuchi.2015.03.002
3. Cipolla-Neto J, Do Amaral FG. Melatonin as a Hormone: New Physiological and Clinical Insights. Vol 39.; 2018. doi:10.1210/er.2018-00084
4. Majidinia M, Reiter RJ, Shakouri SK, Yousefi B. The role of melatonin, a multitasking molecule, in retarding the processes of ageing. Ageing Res Rev. 2018;47(August):198-213. doi:10.1016/j. arr.2018.07.010
5. Hardeland R. Aging, melatonin, and the pro-and anti-inflammatory networks. Int J Mol Sci. 2019;20(5):1-33. doi:10.3390/ijms20051223
6. Lemoine P, Zisapel N. Prolonged-release formulation of melatonin (Circadin) for the treatment of insomnia. Expert Opin Pharmacother. 2012;13(6):895-905. doi:10.1517/14656566.2012.667076
7. Lyseng-Williamson KA. Melatonin prolonged release: In the treatment of insomnia in patients aged ≥55 years. Drugs and Aging. 2012;29(11):911-923. doi:10.1007/s40266-012-0018-z
8. Zisapel N, Lemoine, Garfinkel D, Laudon M, Nir. Prolonged-release melatonin for insomnia – an open-label long-term study of efficacy, safety, and withdrawal. Ther Clin Risk Manag. Published online 2011:301. doi:10.2147/tcrm.s23036
9. Nutriventia by Inventia Healthcare Limited. Melatonin Sustained Release (SR) Granules: Technical Data Sheet. Published online 2021.
10. Pandi-Perumal SR, Trakht I, Srinivasan V, et al. Physiological effects of melatonin: Role of melatonin receptors and signal transduction pathways. Prog Neurobiol. 2008;85(3):335-353. doi:10.1016/j. pneurobio.2008.04.001
11. Chitimus DM, Popescu MR, Voiculescu SE, et al. Melatonin’s impact on antioxidative and anti-inflammatory reprogramming in homeostasis and disease. Biomolecules. 2020;10(9):1-28. doi:10.3390/ biom10091211
12. Gobbi G, Comai S. Sleep well. Untangling the role of melatonin MT1 and MT2 receptors in sleep. J Pineal Res. 2019;66(3):0-3. doi:10.1111/jpi.12544
13. Liu J, Clough SJ, Hutchinson AJ, Adamah-Biassi EB, Popovska-Gorevski M, Dubocovich ML. MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective. Annu Rev Pharmacol Toxicol. 2016;56:361-383.
14. Reiter RJ, Mayo JC, Tan DX, Sainz RM, Alatorre-Jimenez M, Qin L. Melatonin as an antioxidant: under promises but over delivers. J Pineal Res. Published online 2016:253-278. doi:10.1111/jpi.12360
15. Tan DX, Manchester LC, Esteban-Zubero E, Zhou Z, Reiter RJ. Melatonin as a potent and inducible endogenous antioxidant: Synthesis and metabolism. Molecules. 2015;20(10):18886-18906. doi:10.3390/molecules201018886
16. Wade AG, Crawford G, Ford I, et al. Prolonged release melatonin in the treatment of primary insomnia: Evaluation of the age cut-off for short- and long-term response. Curr Med Res Opin. 2011;27(1):87-98. doi:10.1185/03007995.2010.537317
17. Wade AG, Ford I, Crawford G, et al. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: A randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med. 2010;8:1-18. doi:10.1186/1741-7015-8-51
18. Wade AG, Ford I, Crawford G, et al. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: Quality of sleep and next-day alertness outcomes. Curr Med Res Opin. 2007;23(10):2597-2605. doi:10.1185/030079907X233098
19. Lemoine P, Nir T, Laudon M, Zisapel N. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res. 2007;16(4):372-380. doi:10.1111/j.1365-2869.2007.00613.x
20. Luthringer R, Muzet M, Zisapel N, Staner L. The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia. Int Clin Psychopharmacol. 2009;24(5):239-249. doi:10.1097/YIC.0b013e32832e9b08
21. De Leersnyder H, Zisapel N, Laudon M. Prolonged-release melatonin for children with neurodevelopmental disorders. Pediatr Neurol. 2011;45(1):23-26. doi:10.1016/j.pediatrneurol.2011.02.001
22. Gringras P, Nir T, Breddy J, Frydman-Marom A, Findling RL. Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children With Autism Spectrum Disorder. J Am Acad Child Adolesc Psychiatry. 2017;56(11):948-957.e4. doi:10.1016/j.jaac.2017.09.414
23. Maras A, Schroder CM, Malow BA, et al. Long-term efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. J Child Adolesc Psychopharmacol. 2018;28(10):699-710. doi:10.1089/cap.2018.0020
24. Schroder CM, Malow BA, Maras A, et al. Pediatric Prolonged-Release Melatonin for Sleep in Children with Autism Spectrum Disorder: Impact on Child Behavior and Caregiver’s Quality of Life. J Autism Dev Disord. 2019;49(8):3218-3230. doi:10.1007/s10803-019-04046-5
25. Malow BA, Findling RL, Schroder CM, et al. Sleep, Growth, and Puberty After 2 Years of Prolonged-Release Melatonin in Children With Autism Spectrum Disorder. J Am Acad Child Adolesc Psychiatry. 2021;60(2):252-261.
26. Dolberg OT, Hirschmann S, Grunhaus L. Melatonin for the treatment of sleep disturbances in major depressive disorder. Am J Psychiatry. 1998;155(8):1119-1121. doi:10.1176/ajp.155.8.1119
27. Wade AG, Farmer M, Harari G, et al. Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer’s disease: A 6-month, randomized, placebo-controlled, multicenter trial. Clin Interv Aging. 2014;9:947-961. doi:10.2147/CIA.S65625
28. Ahn JH, Kim M, Park S, et al. Prolonged-release melatonin in Parkinson’s disease patients with a poor sleep quality: A randomized trial. Park Relat Disord. 2020;75:50-54. doi:10.1016/j. parkreldis.2020.03.029
29. Agahi M, Akasheh N, Ahmadvand A, Akbari H, Izadpanah F. Effect of melatonin in reducing second-generation antipsychotic metabolic effects: A double blind controlled clinical trial. Diabetes Metab Syndr Clin Res Rev. 2018;12(1):9-15. doi:10.1016/j.dsx.2017.08.004
Quem somos nós?
De uma pequena farmácia, a ArtPharma se tornou hoje a maior Farmácia de Manipulação de toda a região.
E isto não aconteceu por acaso. Foram anos de trabalho! A dedicação de seus profissionais, o respeito à ética e a busca insistente pela qualidade geraram a capacidade de investimento que precisávamos para que, com 15 anos de atividades, viéssemos a ser a primeira farmácia do interior do Estado de São Paulo a conquistar o Certificado de Qualidade ISO 9001.
Quer dar uma volta dentro de nossa loja? Clique aqui e dê um Tour 360!
Continuando sempre a buscar qualidade, mas não esquecendo do respeito ao meio ambiente, com 18 anos de atividades a ArtPharma foi a primeira farmácia da América Latina a conquistar a certificação ambiental ISO 14001.
Ao completar 20 anos de atividades, a ArtPharma foi a primeira farmácia da cidade a obter o selo da Fundação Abrinq como Empresa Amiga da Criança. Além de prezar pela qualidade, pelo respeito ao meio ambiente e pela saúde e bem estar de nossos pacientes, a ArPharma é uma empresa com responsabilidade social.
Por tudo isso, a ArtPharma tem muito a comemorar e, principalmente, a agradecer.
Hoje, com quase 4 décadas de existência, a ArtPharma agradece aos seus clientes, à classe médica e aos seus colaboradores pela confiança, o que tornou possível a realização dessas conquistas.
